KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary
Kidney International,
Год журнала:
2025,
Номер
107(2), С. 234 - 254
Опубликована: Янв. 21, 2025
Язык: Английский
Autosomal Dominant Polycystic Kidney Disease
JAMA,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 24, 2025
Importance
Autosomal
dominant
polycystic
kidney
disease
(ADPKD)
is
characterized
by
progressive
development
of
cysts
and
the
most
common
inherited
disorder
worldwide.
ADPKD
accounts
for
5%
to
10%
failure
in
US
Europe,
its
prevalence
9.3
per
10
000
individuals.
Observations
typically
diagnosed
individuals
aged
27
42
years
primarily
caused
pathogenic
variants
PKD1
(78%)
or
PKD2
(15%)
genes.
Most
persons
with
have
an
affected
parent,
but
de
novo
suggested
25%
families.
More
than
90%
patients
older
35
hepatic
cysts,
which
may
cause
abdominal
discomfort
occasionally
require
medical
surgical
intervention.
Hypertension
affects
70%
80%
ADPKD,
approximately
9%
14%
develop
intracranial
aneurysms,
a
rupture
rate
0.57
1000
patient-years.
Approximately
50%
replacement
therapy
62
age.
The
severity
can
be
quantified
using
Mayo
Imaging
Classification
(MIC),
stratifies
based
on
total
volume
adjusted
height
age
ranges
from
1A
1E.
Patients
MIC
1C
1E
larger
kidneys
because
more
rapid
growth
(6%-10%
year)
compared
those
1B
(1%-5%
earlier
progression
therapy,
occurs
at
mean
58.4
1C,
52.5
1D,
43.4
Optimal
management
includes
systolic
blood
pressure
lower
120
mm
Hg
patients,
110/75
who
estimated
glomerular
filtration
(eGFR)
greater
60
mL/min/1.73
m
2
are
younger
50
years,
dietary
sodium
restriction
(<2000
mg/d),
weight
management,
adequate
hydration
(>2.5
L
daily).
vasopressin
type
receptor
antagonist
tolvaptan
reduces
annual
eGFR
decline
0.98
1.27
indicated
3
year
slow
delay
onset
failure.
Conclusion
genetic
worldwide
cysts.
hypertension
liver
aneurysms.
First-line
treatment
control,
hydration.
Tolvaptan
high
risk
Язык: Английский
Long-term tolvaptan therapy in a case of very early-onset polycystic kidney disease
Pediatric Nephrology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Язык: Английский
Insights from ADPedKD, ERKReg and RaDaR registries provide a multi-national perspective on the presentation of childhood autosomal dominant polycystic kidney disease in high- and middle-income countries.
Kidney International,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Язык: Английский
Index cases of intracranial aneurysms in autosomal dominant polycystic kidney disease: longitudinal experience from a single renal transplantation centre
ANZ Journal of Surgery,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 22, 2025
Abstract
Background
The
prevalence
of
intracranial
aneurysms
(ICAs)
is
higher
in
patients
with
autosomal
dominant
polycystic
kidney
disease
(ADPKD)
than
the
general
population.
This
extrarenal
manifestation
carries
significant
mortality
and
morbidity
risks.
Our
study
aims
to
estimate
of,
characterize
ICA(s)
among
ADPKD
cohort
South
Australia's
statewide
transplantation
centre.
Methods
A
retrospective
review
prospectively
collected
data
was
conducted
for
all
who
underwent
nephrectomy/ies
between
1
January
1995
31
December
2021.
Incidences
neuroimaging
radiologically
diagnosed
ICAs,
presence
risk
factors
including
family
history
are
compared
those
an
alternate
primary
nephrological
diagnosis
(control).
Descriptive
statistics
a
narrative
cases
presented.
Results
Seven
had
ICAs
(14.3%
patients,
23.3%
neuroimaging).
Six
did
not
meet
current
criteria
ICA
screening,
five
no
known
ICA.
Three
suffered
aneurysmal
rupture
(mean
age
36).
Two
these
involved
smaller
ICAs.
Cases
demonstrated
detectable
vascular
changes
on
early
neuroimaging,
hypoplastic
anatomical
variants,
growth,
de
novo
formation,
association
other
abnormalities.
Conclusion
Early
detection
pre‐aneurysmal
should
be
prioritized
ADPKD.
Although
limited
by
small
cohort,
our
findings
consistent
previous
literature
suggesting
ruptures
occur
earlier
aneurysms.
Further
investigation
required
into
how
behave.
Nonetheless,
it
vital
that
centres
coordinate
multidisciplinary,
patient‐centred
approach
surveillance,
management
patients.
Язык: Английский